CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2673
-0.0037 (-1.38%)
As of 2:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2710
Open0.2710
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2673 - 0.2900
52 Week Range0.2673 - 1.3500
Volume60,949
Avg. Volume90,370
Market Cap35.934M
Beta (3Y Monthly)-3.40
PE Ratio (TTM)22.27
EPS (TTM)0.0120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./
    PR Newswireyesterday

    /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

    In the news release, Cannabics Pharmaceuticals Appoints Two Independent Directors, issued June 25, 2019 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the 5th paragraph, 1st sentence, should read "Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv Stock Exchange listed company that is part of the TA-35 and Real-Estate 15 indexes in Israel." rather than as originally issued inadvertently. TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

  • Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada
    PR Newswire22 days ago

    Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

    TEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada. "This year's conference in Toronto is exciting because it is the largest premier industry business conference event in Canada," stated Mr. Barad.

  • ACCESSWIRE27 days ago

    Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

    TEL AVIV, ISRAEL and BETHESDA, MD / ACCESSWIRE / May 30, 2019 / Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California. Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, President at LD Micro.

  • Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City
    PR Newswire2 months ago

    Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City

    TEL AVIV, Israel and BETHESDA, Maryland, April 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, is scheduled to present at the Planet Microcap Conference in Las Vegas, Nevada, being held at the Bally's Hotel, and at the ThinkEquity Conference in New York City being held at The Mandarin Oriental Hotel. Mr. Barad is scheduled to present at the Planet MicroCap conference in Las Vegas at 2pm Pacific Time on May 1, 2019. Mr. Barad will also be speaking at the ThinkEquity conference, at 2pm Eastern Time, on May 2, 2019.

  • Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies
    PR Newswire2 months ago

    Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

    TEL AVIV, Israel and BETHESDA, Maryland, April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies. The apoptotic/cytotoxic effects of a multitude of cannabinoid extracts will be evaluated via Cannabics' high throughput screening platform. Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said: "We believe this is a quantum leap for the research on the biology of cancer and cannabinoids.

  • OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference
    PR Newswire3 months ago

    OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

    OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...

  • SodaStream CEO Daniel Birnbaum to Join Seedo Board
    PR Newswire3 months ago

    SodaStream CEO Daniel Birnbaum to Join Seedo Board

    Seedo Corp. is an agro-tech company providing the world's first fully automated and controlled indoor growing machine for pesticide-free agricultural and vertical farming markets. Cannabics owns approximately 20% of Seedo Corp.'s issued and outstanding common stock.

  • Cannabics Pharmaceuticals Closes Agreement With Wize Pharma
    PR Newswire4 months ago

    Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

    BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.

  • Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics
    PR Newswire4 months ago

    Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics

    Companies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions HOD HASHARON, Israel , March 6 , 2019  /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" ...

  • Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids
    PR Newswire4 months ago

    Cannabics Pharmaceuticals Submits Protocol for an Ex-Vivo Clinical Study on Biopsies and Cannabinoids

    Cannabics has submitted a protocol for the Helsinki Committee to conduct a nationwide study on fresh biopsies treated with a multitude of cannabinoid compounds and chemotherapies TEL AVIV, Israel and BETHESDA, ...

  • Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
    PR Newswire5 months ago

    Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics

    BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Initially announced in a press release on June 29, 2018, the two companies have been advancing planning and have concluded, that subject to completing a mutually agreeable business plan and obtaining an expert opinion in order to identify a potential FDA route for ophthalmic therapy containing cannabinoids, each expected to occur within 30 days, that they are ready to form a joint venture (JV) company, for the purpose of researching, developing, and administering cannabinoid formulations to treat ophthalmic disorder indications.

  • Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions
    PR Newswire5 months ago

    Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions

    HOD HASHARON, Israel, Feb. 7, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreement to form a joint venture (JV) company for the purpose of researching, developing and administering cannabinoid formulations to treat ophthalmic conditions  with Cannabics Pharmaceuticals Inc. ("Cannabics") (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects. The agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids.  Upon effectiveness, Wize shall issue 900,000 shares of its common stock to Cannabics and Cannabics shall issue 2,263,944 shares of its common stock to Wize.  The agreement shall expire if the parties have not approved a business plan by June 30, 2019.

  • Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors
    PR Newswire5 months ago

    Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors

    TEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors. Dr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company's clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE).

  • Cannabics Pharmaceuticals and NewCanna Hub Intend to Collaborate to Manufacture and Market Cannabics' SR Capsules in Colombia
    PR Newswire5 months ago

    Cannabics Pharmaceuticals and NewCanna Hub Intend to Collaborate to Manufacture and Market Cannabics' SR Capsules in Colombia

    TEL AVIV, Israel and BETHESDA, Maryland, Jan. 24, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects announced, that NewCanna Hub, a world leader in the field  of cannabinoids, have signed a non-binding letter of intent ("LOI") today at The World Economic Forum, in Davos, Switzerland, to establish an equal joint venture that is intended to produce and market Cannabics' Slow Release ("SR") capsules in Colombia and, potentially, other regulated markets. Pursuant to the terms of the LOI, the parties intend to develop a joint business plan for the joint venture within the next 30 days and execute a definitive joint venture agreement as soon as reasonably practicable. As part of the new proposed joint venture, the SR capsules are expected to be produced at NewCanna's Good Manufacturing Practice (GMP) certified facility in Columbia in various formulations.

  • Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos
    PR Newswire5 months ago

    Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos

    TEL AVIV, Israel and BETHESDA, Maryland, Jan. 22, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, Co-Founder and CEO, and Dr. Eyal Ballan, Co-Founder and CTO, will be in Davos, Switzerland in January, 2019.

  • Cannabics Pharmaceuticals Converts $1 Million Loan Into Common Shares of Seedo
    PR Newswire6 months ago

    Cannabics Pharmaceuticals Converts $1 Million Loan Into Common Shares of Seedo

    TEL AVIV, Israel, Jan. 8, 2019 /PRNewswire/ -- Seedo Corp. (SEDO), a high-tech company providing the world's first fully automated and controlled indoor growing machine for the organic cannabis and agriculture markets, today announced that U.S.-based partner and investor Cannabics Pharmaceuticals Inc., a leader in personalized cannabinoid medicine focused on cancer and its side effects, is converting its $1 million convertible loan to Seedo into common shares of the company.

  • Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco
    PR Newswire6 months ago

    Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco

    TEL AVIV, Israel and BETHESDA, Md., Dec. 31, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, will be in San Francisco in January 2019 during the J.P. Morgan Healthcare Conference. The company will be meeting with Investors as well as potential partners such as Pharmaceuticals and Biotech firms from Monday, January 7th to Wednesday, January 9th. Mr. Barad will provide an overview on the company's mission and provide insight into the path forward towards bringing a highly valuable and needed solution to cancer patients.

  • Cannabics Pharmaceuticals Announces New Provisional Patent Application for Personalized Cannabimetic Compositions Modeling and Production
    PR Newswire6 months ago

    Cannabics Pharmaceuticals Announces New Provisional Patent Application for Personalized Cannabimetic Compositions Modeling and Production

    TEL AVIV, Israel and BETHESDA, Maryland, Dec. 26, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has filed a provisional patent application with the US Patent office. The patent covers the Company's technology that will enable the transfer of data from its proprietary personalization platform of cannabis strains and cancer to medical cannabis businesses worldwide and overcome the limitations of exporting and importing cannabinoid compounds due to regulation.

  • Market Exclusive6 months ago

    Cannabis Stock News Daily Roundup December 12

    Cannabis News New York-based medical cannabis firm Columbia Care has received approval and license from the State of Virginia to produce cannabis oil. The company, recently valued at $1.35 billion, is planning to open its dispensary in Portsmouth, Virginia, in the spring of 2019. They plan to cultivate, produce and dispense cannabidiol (CBD) and tetrahydrocannabinolic […] The post Cannabis Stock News Daily Roundup December 12 appeared first on Market Exclusive.

  • Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization
    PR Newswire6 months ago

    Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization

    TEL AVIV, Israel and BETHESDA, Maryland, Dec. 11, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has started the accreditation process in accordance with ISO 15189:2012 for its drug screening and diagnostics laboratory, which it expects to receive by the end of next year. ISO is the accepted "International Organization for Standardization", and ISO 15189:2012 is the international standard for quality management and competence for Medical Laboratories by regulators and accrediting bodies.

  • Market Exclusive7 months ago

    Cannabis Stock News Daily Roundup November 29

    The global legal cannabis market is projected to hit $146.4 billion by end of 2025, according to research by Grand View Research. The legal cannabis industry is gaining traction worldwide due to high demand among consumers for recreational and medical products. Recreational cannabis spending is projected to hit $35 Billion mark, while medical cannabis spending […] The post Cannabis Stock News Daily Roundup November 29 appeared first on Market Exclusive.

  • CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California
    PR Newswire7 months ago

    CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California

    TEL AVIV, Israel and BETHESDA, Maryland, Nov. 27, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that Mr. Eyal Barad, CEO, will be presenting at the LD Micro Main Event. The presentation will provide an overview of the company's mission and activities and provide insight into the path forward towards bringing a valuable and needed service to cancer patients, who are using cannabis. Mr. Barad will also describe how the company plans on leveraging its technology to solidify partnerships which create long term value.

  • GlobeNewswire8 months ago

    Cannabics Pharmaceuticals Inc. CEO talks with Uptick Newswire’s Stock Day Podcast About Cancer Research in the Cannabinoid Sector

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) (the “Company”) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. “Cannabics Pharmaceuticals started about 5 years ago and today is mostly focused on the palliative and anti-tumor effects cannabinoids with cancer,” explained Barad.